Autologous TIL therapy Lifileucel in combination with pembrolizumab in anti-PD-1 naïve R/M HNSCC patients showed a response rate of 44% in nine patients with responses ongoing in three out of the four patients at a median follow up of 8.6 months (103). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.